First Trust NYSE Arca Biotech ETF (FBT)

173.25 -1.02  -0.59% NYSE Arca Jul 10, 20:00 Delayed 2m USD
View Full Chart
Price Chart

Key Stats

Net Asset Value 173.15
Discount or Premium to NAV 0.06%
Turnover Ratio 31.00%
1 Year Fund Level Flows -991.22M

Performance & Returns

  Total Return (Price) Total Return (NAV) Cat. Total Return (NAV) % Rank in Cat. (NAV)
1M 4.40% 4.25% 1.84% 19
3M 24.70% 24.64% 17.08% 17
6M 13.40% 13.38% 5.67% 19
YTD 16.49% 16.34% 6.45% 11
1Y 24.01% 23.98% 17.72% 20
3Y 15.17% 15.17% 11.42% 15
5Y 6.96% 6.95% 6.33% 44
10Y 18.69% 18.66% 15.85% 16
15Y -- -- 11.03% --
20Y -- -- 8.76% --
As of July 10, 2020. Returns for periods of 1 year and above are annualized.

Asset Allocation

Type % Net % Long % Short
Cash 0.06% 0.06% 0.00%
Stock 99.94% 99.94% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.00% 0.00% 0.00%
As of July 9, 2020

Region Exposure

Americas 97.41%
North America 97.41%
Latin America 0.00%
Greater Europe 2.59%
United Kingdom 0.00%
Europe Developed 2.59%
Europe Emerging 0.00%
Africa/Middle East 0.00%
Greater Asia 0.00%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.00%
Market Classification
% Developed Markets 100.0%
% Emerging Markets 0.00%
As of July 9, 2020. Region breakdown data is calculated by using the long position holdings of the portfolio.

Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.00%
Energy 0.00%
Financial Services 0.00%
Healthcare 100.0%
Industrials 0.00%
Real Estate 0.00%
Technology 0.00%
Utilities 0.00%
As of July 9, 2020

Stock Market Capitalization

Giant 3.11%
Large 27.50%
Medium 54.33%
Small 15.06%
Micro 0.00%
As of July 9, 2020

Stock Style Exposure

Large Cap Value 8.06%
Large Cap Blend 6.25%
Large Cap Growth 16.30%
Mid Cap Value 3.25%
Mid Cap Blend 6.85%
Mid Cap Growth 44.23%
Small Cap Value 0.00%
Small Cap Blend 3.56%
Small Cap Growth 11.50%
As of July 9, 2020
View More Holdings

Top 10 Holdings

Symbol Name % Weight Price % Chg
RARE Ultragenyx Pharmaceutical Inc 4.36% 86.26 -1.92%
SRPT Sarepta Therapeutics Inc 4.16% 168.81 -0.68%
BMRN Biomarin Pharmaceutical Inc 4.13% 126.06 -0.59%
NBIX Neurocrine Biosciences Inc 3.86% 129.69 -1.42%
SGEN Seattle Genetics Inc 3.85% 174.35 -3.76%
TECH Bio-Techne Corp 3.77% 272.40 -1.79%
CRL Charles River Laboratories International Inc 3.71% 181.25 -2.10%
NKTR Nektar Therapeutics 3.65% 24.02 -1.66%
EXEL Exelixis Inc 3.61% 24.94 +3.14%
EXAS Exact Sciences Corp 3.61% 92.08 -0.72%
As of July 9, 2020
Advertisement

Basic Info

Investment Strategy
The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology IndexSM. The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of small, mid and large capitalization companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services.
General
Security Type Exchange-Traded Fund
Equity Style Mid Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Prospectus Objective Specialty - Health
Fund Owner Firm Name First Trust
Benchmark Index
NYSE Arca Biotechnology TR USD 100.0%
Reports
One Page Report Download

Manager Info

Name Tenure
Chris Peterson 4.29 yrs
Daniel Lindquist 14.04 yrs
David McGarel 14.04 yrs
Jon Erickson 14.04 yrs
Roger Testin 14.04 yrs
Stan Ueland 13.65 yrs

Net Fund Flows

1M 49.87M
3M 258.74M
6M 121.17M
YTD 121.17M
1Y -991.22M
3Y 870.21M
5Y -731.49M
10Y 1.513B
As of June 30, 2020

Risk Info

Beta (5Y) 1.310
Max Drawdown (All) 40.51%
Historical Sharpe Ratio (10Y) 0.8346
Historical Sortino (All) 1.028
30-Day Rolling Volatility 23.59%
Daily Value at Risk (VaR) 1% (All) 4.40%
Monthly Value at Risk (VaR) 1% (All) 21.44%

Fundamentals

Dividend Yield TTM (7-10-20) 0.00%
30-Day SEC Yield --
7-Day SEC Yield --
Weighted Average PE Ratio 24.38
Weighted Average Price to Sales Ratio 7.313
Weighted Average Price to Book Ratio 5.105
Weighted Median ROE -4.47%
Weighted Median ROA -6.43%
Forecasted Dividend Yield 0.23%
Forecasted PE Ratio 23.60
Forecasted Price to Sales Ratio 6.249
Forecasted Price to Book Ratio 4.262
Number of Holdings 31
As of July 9, 2020

Growth Estimates

Forecasted 5 Yr Earnings Growth 14.68%
Forecasted Book Value Growth 7.90%
Forecasted Cash Flow Growth 12.63%
Forecasted Earnings Growth 18.76%
Forecasted Revenue Growth 10.62%
As of July 9, 2020

Comparables

Edit

Attributes

Key Dates
Inception Date 6/19/2006
Termination Date
Last Annual Report Date 12/31/2019
Last Prospectus Date 5/1/2020
Attributes
Exchange Traded Share Yes
Exchange Traded Note No
Enhanced Index Fund No
Fixed Distribution Fund No
High-Net Worth Individual Fund No
Index Fund Yes
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.